

CAR T cell robots based on magneticacoustic actuation developed for precise antitumor immunotherapy



Schematic illustration of M-CAR T microrobots based on magnetic-acoustic sequential actuation for self-controllable guidance towards solid tumors. Credit:



SIAT

Although chimeric antigen receptor (CAR) T cell therapy has shown potential in the treatment of hematological malignancies, its application in solid tumors is unsatisfactory due to the harsh physical barriers and immunosuppressive microenvironment.

The ideal CAR T therapy requires a novel armored CAR T cell engineered to navigate in the <u>circulatory system</u>, penetrate <u>tumor</u> tissues, and survive in the harsh tumor microenvironment to exert adequate immune effects.

Recently, a research team led by Prof. Cai Lintao from the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences has developed a CAR T cell-based microrobot (M-CAR T) with magnetic-acoustic sequential actuation that can autonomously navigate to tumor sites for cell immunotherapy by decorating CAR T with immunomagnetic beads using click conjugation.

The study was published in Advanced Materials on Feb. 17.

Based on immunomagnetic bead engineering, the M-CAR T demonstrated controllable anti-flow and obstacle avoidance movement and maintained an on-demand route under magnetic guidance. Meanwhile, it exhibited distinctive, acoustic manipulative properties whereby it could exert CAR T cell control and could actively penetrate artificial tumor tissues under magnetic-acoustic sequential actuation.

"Sequential actuation endows M-CAR Ts with magnetically actuated antiflow and obstacle avoidance capabilities as well as acoustically actuated tumor tissue penetration, which enables efficient migration and



accumulation in artificial tumor models," said Prof. Cai.

In animal models, M-CAR Ts with sequential actuation achieved longdistance targeting and accumulated at the peritumoral area under programmable magnetic guidance. Subsequently, acoustic tweezers actuated M-CAR Ts to migrate into deep tumor tissues, resulting in a 6.6-fold increase in accumulated exogenous CD8⁺ CAR T cells compared with those with no actuation.

"Ingeniously, anti-CD3/CD28 immunomagnetic beads stimulate infiltrated CAR T proliferation and activation in situ, significantly enhancing their antitumor immune efficacies," said Dr. Pan Hong, cocorresponding author of the study.

The M-CAR T maintains the bioactive properties of CAR T cells and is capable of magnetically propelled spatial targeting and acoustically actuated tumor penetration to cope with vascular anti-flow and obstacles to migrating into deep tumor. After entering <u>tumor tissues</u>, immunomagnetic beads in situ stimulated CAR T cells to overcome immunosuppressive tumor environments through efficient expansion and activation.

"Such sequential actuation-guided cell microrobots combine the merits of autonomous targeting and penetration of intelligent robots with in-situ immunoactivation of T cells. It holds considerable promise for clinical precision immunotherapies of solid cancer," said Dr. Pan.

More information: Xiaofan Tang et al, Magnetic-acoustic Sequentially Actuated CAR T cell Microrobots for Precision Navigation and in-situ Antitumour Immunoactivation, *Advanced Materials* (2023). DOI: 10.1002/adma.202211509



Provided by Chinese Academy of Sciences

Citation: CAR T cell robots based on magnetic-acoustic actuation developed for precise antitumor immunotherapy (2023, March 15) retrieved 8 May 2024 from <u>https://medicalxpress.com/news/2023-03-car-cell-robots-based-magnetic-acoustic.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.